NCT02515305已完成3 期
Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Padagis LLC
- 入组人数
- 890
- 试验地点
- 1
- 主要终点
- Mean Percent Change From Baseline in Inflammatory (Papules and Pustules) Lesions
研究概览
简要总结
The purpose of this study is to compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment acne vulgaris
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 12 Years 至 40 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide written informed consent/assent
- •Healthy male or non-pregnant females, 12 to 40 years of age, inclusive
- •Definite clinical diagnosis of acne vulgaris with an inflammatory lesion (papules and pustules) count between 20 and 50 and a non-inflammatory (open and closed comedones) lesion count between 25 and 100 and no more than 2 nodulocystic lesions (i.e., nodules and cysts) including those present on the nose.
- •Baseline IGA score of 3 or 4 on a scale of 0 to
- •Willing and able to understand and comply with the requirements of the study, apply the medication as instructed, refrain from use of all other topical acne medication or topical antibiotics during the 12-week treatment period, return for the required treatment period visits, comply with therapy prohibitions, and are able to complete the study.
- •Be in general good health and free from any clinically significant disease, other than acne vulgaris, that might interfere with the study evaluations.
- •Females of childbearing potential willing to use an acceptable form of birth control
排除标准
- •Females who are pregnant, nursing, or planning a pregnancy within the study participation period
- •More than 2 facial nodulocystic lesions (i.e. nodules and cysts).
- •Acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne, etc.).
- •Active cystic acne or Polycystic Ovarian Syndrome.
- •History or presence of Crohn's disease, ulcerative colitis, regional enteritis, inflammatory bowel disease, pseudomembranous colitis, chronic or recurrent diarrhea or antibiotic-associated colitis.
- •Use of neuromuscular blocking agents (nondepolarizing agents and depolarizing agents) Subjects who have had general anesthesia for any reason and subjects who have received neuromuscular blocking agents within 14 days prior to study entry will be excluded from study participation.
- •Presence of any other facial skin condition that might interfere with acne vulgaris diagnosis and/or assessment (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid folliculitis, sunburn or bacterial folliculitis).
- •Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris.
- •History of unresponsiveness to topical Clindamycin Phosphate and/or benzoyl peroxide therapy.
- •Use of systemic Clindamycin products 4 weeks (30 days) prior to baseline or throughout the study.
- •History of hypersensitivity or allergy to Clindamycin Phosphate, benzoyl peroxide and/or any ingredient in the study medication.
- •Use within 6 months (180 days) prior to baseline or during the study of oral retinoids (e.g. Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
- •Use of radiation therapy and/or anti-neoplastic agents within 90 days prior to Visit 1/Day 1 (Baseline).
- •Use within 30 days (1 month) prior to baseline or during the study of therapeutic vitamin D supplement (daily multivitamins with total 800IU Vitamin D are allowed).
- •Use of medications known to exacerbate acne (Vitamin B12, lithium, corticosteroids; Vitamin B12, etc. as part of a multivitamin regimen is allowed).
- •Start or change of dose of hormonal treatment (oral, implanted, topical contraceptives and androgens) 3 months (90 days) prior to baseline or throughout the study. Use of such therapy must remain constant during the study.
- •Use of medicated make-up throughout the study and significant change in the use of consumer products within 30 days (1 month) of study entry and throughout the study (other than study supplied cleanser and lotion).
- •Use within 30 days (1 month) prior to baseline or during the study of 1) spironolactone, 2) systemic steroids*, 3) systemic (e.g., oral or injectable) antibiotics, 4) systemic treatment for acne vulgaris (other than oral retinoids which require a 6-month washout), or 5) immunosuppressive agents**. (*Intranasal and inhaled corticosteroids do not require a washout and may be used throughout the study if at a stable and standard dose.)** Subjects may use systemic anti-inflammatory agents (i.e., NSAIDs (Ibuprofen or Aspirin) for pain relief) as needed (with no more than 7 days of consecutive use) throughout the study. Prophylactic use of low dose Aspirin 81 mg is allowed. *** Subjects may use Acetaminophen for pain relief, as needed throughout the study
- •Use within 14 days (2 weeks) prior to baseline or during the study of 1) topical steroids, 2) topical retinoids, 3) topical anti-acne medications (e.g. Benzoyl peroxide, retinoids, azelaic acid, α-hydroxy/glycolic acid, Clindamycin, etc.) including OTC preparations 4) topical anti-inflammatory agents, or 5) topical antibiotics.
- •Use on the face within 1 month (30 days) prior to baseline or during the study of 1) cryodestruction or chemodestruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne surgery, 5) intralesional steroids, or 6) x-ray therapy.
- •Use of medicated cleansers (e.g. benzoyl peroxide, salicylic acid, sulfur or triclosan) within 2 weeks (14 days) of study start and throughout the study.
- •Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subject's ability to comply with study requirements.
- •Use of Antipruritics, including antihistamines within 24 hours (1day) of all study visits (Visit 1 through Visit 4).
- •Participation in any clinical study involving an investigational product, agent or device ( that might influence the intended effects or mask the side effects of study medication ) in the 4 weeks (30 days) prior Visit 1/Day 1 (Baseline) or throughout the study.
- •Previous enrollment in this study or current enrollment in this study at another participating site.
- •Employee (or employee's family member) of the research center or private practice, or subjects who have a conflict of interest.
- •Use of tanning booths, sun lamps, sunbathing or excessive exposure to the sun 1 week (7 days) prior to enrollment and throughout the study.
- •Subjects who in the opinion of the investigator, are unlikely to be able to follow the restrictions of the protocol and complete the study.
研究组 & 干预措施
Test product
Experimental
干预措施: Clindamycin and Benzoyl Peroxide Gel (combination) (Drug)
Reference product
Active Comparator
干预措施: Clindamycin and Benzoyl Peroxide Gel (Reference) (combination) (Drug)
Placebo product
Placebo Comparator
干预措施: Placebo gel (combination) (Drug)
结局指标
主要结局
Mean Percent Change From Baseline in Inflammatory (Papules and Pustules) Lesions
时间窗: Baseline to Day 84
Mean Percent Change From Baseline in Non-inflammatory (Open and Closed Comedones) Lesions
时间窗: Baseline to Day 84
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of RosaceaRosaceaNCT02795117Padagis LLC486
已完成
3 期
Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal AtrophyAtrophyNCT02770365Padagis LLC695
已完成
3 期
To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic KeratosisActinic KeratosisNCT02459795Padagis LLC469
已完成
3 期
To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic KeratosisActinic KeratosisNCT02385318Padagis LLC519
已完成
3 期
Comparative Safety and Bioequivalence of Two Treatments in the Treatment of Acne VulgarisAcneNCT02525549Padagis LLC903